NCT02500602View on ClinicalTrials.gov

CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders

PHASE2CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

December 16, 2019

Study Completion Date

December 16, 2019

Conditions
Posttraumatic Stress DisorderAlcohol Use Disorders
Interventions
DRUG

doxazosin

active medication

DRUG

placebo

placebo pill

Trial Locations (1)

29401-5799

Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston

All Listed Sponsors
collaborator

Medical University of South Carolina

OTHER

lead

VA Office of Research and Development

FED

NCT02500602 - CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders | Biotech Hunter | Biotech Hunter